The methyltransferase inhibitor 5-aza-2-deoxycytidine induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells

被引:40
作者
Hsi, LC [1 ]
Xi, XP [1 ]
Wu, YQ [1 ]
Lippman, SM [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77230 USA
关键词
D O I
10.1158/1535-7163.MCT-05-0218
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
DNA methylation by DNA methyltransf erases in CpG-rich promoter regions of genes is a well-described component of epigenetic silencing in human cells. Dysregulation of this process in cancer cells may lead to hypermethylation of promoter CpG islands, thus disabling transcription initiation of certain genes, such as tumor suppressor genes. Reversing epigenetic silencing and up-regulating genes involved in preventing or reversing the malignant phenotype has become a new, important targeted approach for cancer prevention and treatment. Therefore, methyltransf erase inhibitors (MTI) have emerged recently as promising chemotherapeutic or preventive agents. The potent MTI 5-aza-2-deoxycytidine (5-Azadc) causes growth arrest, differentiation, and/or apoptosis of many tumor types in vitro and in vivo. The present study shows that low micromolar concentrations of 5-Azadc induce the expression of 15lipoxygenase-1 (15-LOX-1) in human colorectal cancer cells. The expression of 15-LOX-1 correlates with 5-Azadc-induced increases in 13-S-hydroxyoctadecadienoic acid levels, growth inhibition, and apoptosis in these cells. Furthermore, specific inhibition of 15-LOX-1 by pharmacologic means or small interfering RNA significantly reduced the 5-Azadc-induced effects. These novel findings are the first demonstration of a mechanistic link between the induction of 15-LOX-1 by a MTI and apoptosis in cancer cells. This result has important implications for the study of 5-Azadc and other MTIs in the prevention and therapy of colorectal cancer and supports future investigations of the mechanisms by which MTls up-regulate 15-LOX-1.
引用
收藏
页码:1740 / 1746
页数:7
相关论文
共 44 条
[1]   Phase I trial of continuous infusion 5-aza-2′-deoxycytidine [J].
Aparicio, A ;
Eads, CA ;
Leong, LA ;
Laird, PW ;
Newman, EM ;
Synold, TW ;
Baker, SD ;
Zhao, M ;
Weber, JS .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 51 (03) :231-239
[2]   Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene [J].
Bachman, KE ;
Park, BH ;
Rhee, I ;
Rajagopalan, H ;
Herman, JG ;
Baylin, SB ;
Kinzler, KW ;
Vogelstein, B .
CANCER CELL, 2003, 3 (01) :89-95
[3]   DNA methylation patterns and epigenetic memory [J].
Bird, A .
GENES & DEVELOPMENT, 2002, 16 (01) :6-21
[4]  
Brown Robert, 2004, Expert Rev Anticancer Ther, V4, P501, DOI 10.1586/14737140.4.4.501
[5]   Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer [J].
Cameron, EE ;
Bachman, KE ;
Myöhänen, S ;
Herman, JG ;
Baylin, SB .
NATURE GENETICS, 1999, 21 (01) :103-107
[6]   Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment [J].
Daskalakis, M ;
Nguyen, TT ;
Nguyen, C ;
Guldberg, P ;
Köhler, G ;
Wijermans, P ;
Jones, PA ;
Lübbert, M .
BLOOD, 2002, 100 (08) :2957-2964
[7]   Measurement of the linking number change in transcribing chromatin [J].
Drabik, CE ;
Nicita, CA ;
Lutter, LC .
JOURNAL OF MOLECULAR BIOLOGY, 1997, 267 (04) :794-806
[8]   Epigenetics in human disease and prospects for epigenetic therapy [J].
Egger, G ;
Liang, GN ;
Aparicio, A ;
Jones, PA .
NATURE, 2004, 429 (6990) :457-463
[9]   The clinical application of targeting cancer through histone acetylation and hypomethylation [J].
Gilbert, J ;
Gore, SD ;
Herman, JG ;
Carducci, MA .
CLINICAL CANCER RESEARCH, 2004, 10 (14) :4589-4596
[10]   Mechanisms of disease: Gene silencing in cancer in association with promoter hypermethylation [J].
Herman, JG ;
Baylin, SB .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (21) :2042-2054